BEVACIZUMAB (AVASTIN)

Course overview

Bevacizumab is FDA-approved to treat recurrent progressive glioblastoma; metastatic colorectal cancer combined with 5-fluorouracil-based therapy; metastatic renal cell carcinoma combined with interferon alfa; and non-squamous non-small-cell lung cancer combined with paclitaxel/carboplatin. This continuing education module is designed to give the reader/learner an increased understanding of bevacizumab. Readers may explore any or all of the topics. One contact hour of continuing education credit is available for those who successfully complete the post-test and evaluation form.